Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Cash & Equivalents (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Cash & Equivalents for 16 consecutive years, with $174.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 141.92% to $174.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $174.9 million through Dec 2025, up 141.92% year-over-year, with the annual reading at $174.9 million for FY2025, 141.92% up from the prior year.
  • Cash & Equivalents hit $174.9 million in Q4 2025 for Ligand Pharmaceuticals, up from $139.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $174.9 million in Q4 2025 to a low of $4.1 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $48.0 million across 5 years, with a median of $30.1 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: tumbled 94.87% in 2021 and later skyrocketed 491.8% in 2023.
  • Year by year, Cash & Equivalents stood at $19.5 million in 2021, then skyrocketed by 130.54% to $45.0 million in 2022, then plummeted by 49.0% to $23.0 million in 2023, then skyrocketed by 215.01% to $72.3 million in 2024, then surged by 141.92% to $174.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for LGNDZ at $174.9 million in Q4 2025, $139.4 million in Q3 2025, and $67.7 million in Q2 2025.